Physician profile
Kellyn V Mcmahon
NPI 1629376611
$39,264.62
in general payments reported to CMS, 2019-2025
8 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $12K · 2023: $8,829 · 2024: $117 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,520 · Honoraria: $2,000 · Travel and Lodging: $995 · Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,520.00 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $994.85 |
| Food and Beverage | $971.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,747.23 | 2021-2024 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $7,462.05 | 2021-2023 | Korsuva, Velphoro |
| Vifor Pharma, INC. | $5,886.13 | 2021-2025 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $1,037.10 | 2021-2023 | Auryxia |
| Travere Therapeutics, INC. | $53.07 | 2023-2024 | |
| Boston Scientific Corporation | $30.43 | 2022 | |
| Kyowa Kirin, INC. | $29.22 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $19.39 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellyn Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.